HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.1841
https://www.valueinhealthjournal.com/article/S1098-3015(23)04971-9/fulltext
Section Title :
Section Order :
11281
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04971-9&doi=10.1016/j.jval.2023.09.1841